Last reviewed · How we verify
NCT03600961: BIOFLOW-SV
BIOFLOW-SV Portugal Registry
trial testing Orsiro Sirolimus Eluting Coronary Stent System in Ischemic Heart Disease in 173 participants. Terminated before completion.
30 December 2020
Quick facts
| Lead sponsor | Biotronik AG |
|---|---|
| Status | Terminated |
| Study type | OBSERVATIONAL |
| Enrollment | 173 |
| Start date | 5 July 2018 |
| Primary completion | 30 December 2020 |
| Estimated completion | 21 December 2021 |
| Sites | 4 locations across Portugal |
Drugs / interventions tested
- Orsiro Sirolimus Eluting Coronary Stent System
Conditions studied
- Ischemic Heart Disease — all drugs for Ischemic Heart Disease →
Sponsor
Biotronik AG
Who can join
18 and older, any sex, with Ischemic Heart Disease. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Assessment of the clinical safety and performance of the Orsiro drug-eluting stent in a real world setting in patients with small vessels with reference vessel diameter ≤2.75 mm
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT03600961
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Orsiro Sirolimus Eluting Coronary Stent System
Trials testing the same drug.
- NCT03600948 — BIOFLOW-SV All Comers Registry · terminated
Other recruiting trials for Ischemic Heart Disease
Currently open trials in the same condition.
- NCT07399002 — LONG NAGOMI™ PMCF STUDY · recruiting
- NCT07083557 — Routine Validation and Reproducibility Testing of Laboratory Assays and Research Techniques Used for Endocrine, Cardiome · recruiting
- NCT06712862 — A Clinical Study of Evaluating Myocardial Viability in Ischemic Heart Disease with Integrated 18F-FDG PET/MR · recruiting
- NCT07009418 — Smart Angioplasty Research Team-Coronary CT Angiography Versus Standard Care as Follow-up Strategies in High-Risk Patien · NA · recruiting
- NCT06891456 — Pulsed Field Ablation for Post-Infarction Ventricular Tachycardia · NA · recruiting
Other Biotronik AG trials
Trials by the same sponsor.
- NCT06758921 — Prospective, Multicenter, Single-Arm Observational Study to Confirm the Safety and Clinical Performance of the Oscar Per · recruiting
- NCT05831319 — Evaluation of Standard of Care Practices, Procedural Outcomes and In-hospital Complications of Peripheral Endovascular P · completed
- NCT04830228 — BIOTRONIK Dynetic-35 Stent for the Treatment of Peripheral Iliac Lesions · active not recruiting
- NCT04555174 — BIOFLOW-VIII All-comers Orsiro Mission Safety and Performance Registry · active not recruiting
- NCT04250909 — Retrospective Follow-up of BIOLUX P-I/-II · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03600961 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Biotronik AG
- Last refreshed: 15 February 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03600961.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing